OncoMatch

OncoMatch/Clinical Trials/NCT07753499

Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer

Is NCT07753499 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for tumor.

NARecruitingThe First Affiliated Hospital of Xiamen UniversityNCT07753499Data as of Sep 2026Location: China

In this study, we comprehensively evaluated the clinical utility of Trop2 PET/CT (68Ga-MY6349 PET/CT) imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with those of 68Ga-FAPI PET/CT. The primary objective of this study was to evaluate the patient-based sensitivity of 68Ga-MY6349 PET/CT in detecting recurrent and metastatic thyroid cancer. The secondary objectives included its overall specificity, lesion-based diagnostic performance, comparative tumor uptake relative to 68Ga-FAPI PET/CT, and the impact on clinical management.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Thyroid Gland Carcinoma

Biomarker criteria

Required: TG expression (Tgon ≥1 ng/mL after 131I ablation or ≥5 ng/mL without ablation)

elevated thyrotropin suppressed thyroglobulin (Tgon ≥1 ng/mL after 131I ablation or ≥5 ng/mL without ablation) with negative anti thyroglobulin antibodies (<20 IU/mL) for DTC and HGFCTC

Required: CALCA expression (calcitonin >10 pg/mL)

elevated calcitonin (>10 pg/mL) for MTC

Disease stage

Metastatic disease required

recurrent and metastatic thyroid cancer

Demographics

Ages ≤ 90

Prior therapy

Must have received: thyroidectomy

DTC and HGFCTC following thyroidectomy with or without 131I therapy, MTC after thyroidectomy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07753499 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received thyroidectomy.

Does this trial require TG?

Yes, TG expression is a required biomarker for enrollment.

Does this trial require CALCA?

Yes, CALCA expression is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 90 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify